Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > More take outs brewing in the mj industry
View:
Post by mdjbrown on May 10, 2021 9:42am

More take outs brewing in the mj industry

Trulieve Cannabis to acquire Harvest Health for $2.1B

2021-05-10 09:37 ET - News Release

Also News Release (C-HARV) Harvest Health & Recreation Inc

Ms. Kim Rivers of Trulieve reports

TRULIEVE ANNOUNCES THE LARGEST US CANNABIS TRANSACTION; ACQUISITION OF HARVEST HEALTH & RECREATION INC., CREATES THE MOST PROFITABLE MULTI-STATE OPERATOR IN THE WORLD'S LARGEST CANNABIS MARKET

Trulieve Cannabis Corp. and Harvest Health & Recreation Inc. have entered into a definitive arrangement agreement, pursuant to which Trulieve will acquire all of the issued and outstanding subordinate voting shares, multiple voting shares and supervoting shares of Harvest. Under the terms of the Arrangement Agreement, shareholders of Harvest (the "Harvest Shareholders") will receive 0.1170 of a subordinate voting share of Trulieve (each whole share, a "Trulieve Share") for each Harvest subordinate voting share (or equivalent) held (the "Exchange Ratio"), representing total consideration of approximately $2.1 billion based on the closing price of the Trulieve Shares on May 7, 2021.

Trulieve, a leading multi-state operator with a focus on the northeast and southeast regions of the United States, and Harvest, a leading multi-state operator with a focus on the west coast and northeast regions of the United States, have built deep, vertically integrated operations in their key markets, becoming leading operators in the United States, the world's largest regulated cannabis market.

Upon completion of the Transaction, as well as the closing of other previously announced acquisitions by Harvest and Trulieve, the combined business will have operations in 11 states, comprised of 22 cultivation and processing facilities with a total capacity of 3.1 million square feet, and 126 dispensaries serving both the medical and adult-use recreational cannabis markets.

Key Transaction Highlights and Benefits

Increases Scale Across Our Hub Markets - through the creation of the largest U.S. cannabis operator on a combined retail and cultivation footprint basis;

Creates the Most Profitable US MSO - with combined 2020 Adjusted EBITDA of $266 million 1,2 and combined 2021E consensus Adjusted EBITDA3 of $461 million, delivering an unparalleled platform for continued growth;

Delivers a Superior Existing Retail and Distribution Model - from a robust retail network of 126 dispensaries across 11 states, the combined company will have leading market shares in Arizona and Florida;

Strong and Expanding Multi-State Presence - bolsters Trulieve's expansion in US northeast and southeast hubs in Florida, Pennsylvania and Maryland, and establishes a southwest hub in core markets including Arizona, where recreational adult use of cannabis was recently legalized;

Optimizes Nationwide Presence - through well-established retail and wholesale channels across markets, as well as the ability to reach an estimated total addressable market of US$19.3 billion in 2025E (Arcview market estimate);

Adds Premium Brands - to Trulieve's portfolio of in-house brands and national brand partners with a successful line of products across multiple form factors;

Leverages Expert Operating Teams and Best Practices - from each of Trulieve and Harvest, enhancing operational excellence by combining unparalleled knowledge of, and success in winning, state license application processes and the ability to rapidly bring operations to market; and

Accretive Transaction Reinforces Trulieve's Leading Financial Metrics - by reinforcing superior financial performance relative to peers through industry-leading margins and strong projected profitable growth.

Management Commentary

"Today's announcement is the largest and most exciting acquisition so far in our industry, creating the most profitable public multi-state operator. Importantly, our companies share similar customer values with a focus on going deep in core markets. This combination offers us the opportunity to leverage our respective strong foundations and propel us forward with an unparalleled platform for future growth," stated Kim Rivers, Chief Executive Officer of Trulieve. "Harvest provides us with an immediate and significant presence in new and established markets and accelerates our entry into the adult use space in Arizona. Trulieve and Harvest are leaders in our markets, recognized for our innovation, brands, and operational expertise with true depth and scale in our businesses. We look forward to providing best-in-class service to patients and customers on a broader national scale as we create an iconic US cannabis brand."

"We are thrilled to be joining Trulieve, a company that has achieved unrivaled success and scale in its home state of Florida," said Steve White, Chief Executive Officer of Harvest. "As one of the oldest multi-state operators, we believe our track record of identifying and developing attractive market opportunities combined with our recent successful launch of adult use sales in Arizona will add tremendous value to the combined organization as it continues to expand and grow in the coming years."

Comment by allibabba on May 10, 2021 12:18pm
It's the 11th hour for labs.  They can sign a deal in every country in the world and it won't matter one bit.  There are many big pharma companies that have all the capabilities labs has, including GW pharma, valens and many others.  They don't have anything that others don't already have, them saying they are a pharma leader is the same as oils saying their ...more  
Comment by Hound0610 on May 10, 2021 2:08pm
Absolutely not true. If it was that easy all big pharmacy would already be doing it. Instead they buy into or acquure companies. Admit it you never have anything positive about this Company Then why be here
Comment by Righttothetop on May 10, 2021 2:48pm
I have had plenty positive to say about the company but my patience has worn thin.  And I don't exit because I am on record with being a bag holder and it makes no sense to crystallize my loses at this point, so I may as well stay the course for good or for bad. And it is that easy Hound...don't kid yourself.  Do you think that any big pharma with hundreds of millions if not ...more  
Comment by Hound0610 on May 10, 2021 3:48pm
I am a bag holder as well. I think you are totally under estimating the simplicity of big pharna or other companies venturing a start up on their own. This is why companies are hooking up with existing companies such as Stada Molsons, I agree VALENS is at present a better run company. Are value will rise as these contracts show $$$$ value, and I and when they get the CEO provided the right person ...more  
Comment by allibabba on May 10, 2021 4:37pm
I am also a bad holder, which is why I'm still here praying to recover some of my money.  My point is that big pharma players already have Gmp, they already have licenses they already have teams of scientist and customers around the world.  The only thing they would need to do is buy a million dollar extractor and they would be at the same point.  I'm still pessimisticly ...more  
Comment by Hound0610 on May 10, 2021 7:26pm
Not if all the contracts that commenced Jan 2021 come to fruition
Comment by Righttothetop on May 11, 2021 7:10am
I agree that the CEO will be a pretty big turning point.  I'm hoping it's a needle moving person, but I've had my hopes dashed on stuff like that before.  I have no doubt every middle management pharma sales monkey in Canada contacted Korn Ferry; who wouldn't want a CEO title on their resume even if they run it right into the rocks. I've said it before that 2021 will ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities